TherapeuticsMD (TXMD) Depreciation & Amortization - Total (2011 - 2023)

TherapeuticsMD (TXMD) has reported Depreciation & Amortization - Total for 7 consecutive years, with $100000.0 the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Depreciation & Amortization - Total fell 50.0% year-over-year to $100000.0; the trailing twelve-month figure through Dec 2023 stood at $100000.0 (down 85.71% YoY), and the FY2023 full-year result was $100000.0, down 83.33% from the prior year.
• Depreciation & Amortization - Total fell to $100000.0 in Q4 2023 per TXMD's latest filing, from $200000.0 in the prior quarter.
• Across five years, Depreciation & Amortization - Total topped out at $200000.0 in Q2 2022 and bottomed at $66556.0 in Q2 2019.
• Historically, Depreciation & Amortization - Total has averaged $144426.0 across 3 years, with a median of $150000.0 in 2022.
• The sharpest annual moves came in 2019 and 2023: Depreciation & Amortization - Total soared 63.22% in 2019, then slumped 50.0% in 2023.
• Over 3 years, Depreciation & Amortization - Total stood at $66556.0 in 2019, then surged by 200.5% to $200000.0 in 2022, then plunged by 50.0% to $100000.0 in 2023.
• According to Business Quant data, Depreciation & Amortization - Total over the past three periods registered $100000.0, $200000.0, and $200000.0 for Q4 2023, Q4 2022, and Q3 2022 respectively.